Comparable to prophylactic models, both KLH–GP2–P4 and KLH–GP2 exhibited therapeutic activity by significantly inhibiting the tumor growth in the tumored mice (p < 0.01) in comparison to the untreated tumored mice group (Figure 7A). This evidence concerns the gene GP2 and neoplasm.